^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

ALPP-targeted CAR-T immunotherapy

2ms
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=20, Recruiting, Xinqiao Hospital of Chongqing | Suspended --> Recruiting
Enrollment open • CAR T-Cell Therapy • Metastases
|
MSLN (Mesothelin)
|
MSLN positive
|
cyclophosphamide • TC-A101
2ms
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=9, Recruiting, Xinqiao Hospital of Chongqing | Suspended --> Recruiting
Enrollment open • CAR T-Cell Therapy • Metastases
|
cyclophosphamide • fludarabine IV
3ms
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=9, Suspended, Xinqiao Hospital of Chongqing | Recruiting --> Suspended
Trial suspension
|
cyclophosphamide • fludarabine IV
3ms
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=20, Suspended, Xinqiao Hospital of Chongqing | Recruiting --> Suspended
Trial suspension
|
MSLN (Mesothelin)
|
MSLN positive
|
cyclophosphamide • TC-A101
3ms
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
P1, N=60, Active, not recruiting, Arsenal Biosciences, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MUC16 (Mucin 16, Cell Surface Associated)
|
BRCA2 mutation • BRCA1 mutation
|
cyclophosphamide • AB-1015
4ms
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=20, Recruiting, Xinqiao Hospital of Chongqing | Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> May 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
Enrollment open • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
|
MSLN (Mesothelin)
|
cyclophosphamide • TC-A101
8ms
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
P1, N=60, Recruiting, Arsenal Biosciences, Inc. | Trial primary completion date: Mar 2024 --> Dec 2024
Trial primary completion date
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MUC16 (Mucin 16, Cell Surface Associated)
|
BRCA2 mutation • BRCA1 mutation
|
cyclophosphamide • AB-1015